The financial landscape for Oscar Health, Inc. (NASDAQ:OSCR) experienced a significant event on June 23, 2026, marked by a substantial divestiture by director Mario Schlosser. Mr. Schlosser sold Class A common stock with a total value of approximately $30.18 million. These transactions were executed under the framework of a Rule 10b5-1 trading plan, a regulatory provision that enables insiders to establish predetermined schedules for buying or selling company stock, thereby facilitating planned liquidity events.
The scope of the divestiture encompassed 1,027,490 shares of Class A common stock. The execution prices for these shares varied, ranging from $28.08 to $30.09 per share. This activity occurs against a backdrop of notable stock performance for Oscar Health. The stock was recently trading at $28.46, a level near its 52-week high of $30.66. This valuation reflects a remarkable 105% surge over the past six months. Despite this strong upward trajectory, data from InvestingPro indicates that the stock remains highly volatile, characterized by a beta of 2.39. Furthermore, fair value analysis from the platform suggests the stock is currently trading near its fair value assessment.
The structure of the sales involved a mix of direct and indirect holdings. Mr. Schlosser directly sold 879,990 shares. The remaining portion of the transaction involved indirect sales facilitated through three distinct family trusts: the Noah Pizzo-Schlosser Dynasty Trust, the Siena Pizzo-Schlosser Dynasty Trust, and the Pizzo-Schlosser Family Dynasty Trust. These trusts collectively sold 147,500 shares. It is important to note that Mr. Schlosser disclaims beneficial ownership over the shares held of record by these trusts, except to the extent of his pecuniary interest therein, if any.
Contextualizing the liquidity event, prior to these sales, Mr. Schlosser acquired 1,027,500 shares of Class A common stock through the conversion of Class B common stock. These conversions occurred at no cost per share, as Class B common stock is convertible into Class A common stock on a one-to-one basis. This acquisition included 880,000 shares obtained directly and 147,500 shares acquired indirectly through the aforementioned trusts. Additionally, Mr. Schlosser exercised options to acquire 660,000 shares of Class B common stock at an exercise price of $9.75 per share. These options were fully vested and exercisable.
Following the reported transactions, Mr. Schlosser's direct holdings consist of 480,866 shares of Class A common stock, which includes shares to be issued in connection with the vesting of restricted stock units. The Noah Pizzo-Schlosser Dynasty Trust, Siena Pizzo-Schlosser Dynasty Trust, and Pizzo-Schlosser Family Dynasty Trust each hold 0 shares of Class A common stock following these transactions.
Concurrent with the insider activity, Oscar Health has seen significant developments in analyst sentiment and corporate structure. Barclays upgraded Oscar Health to an Overweight rating from Equalweight, raising the price target to $35.00. This upgrade cites potential for valuation growth and margin recovery. Wells Fargo also upgraded the company’s stock rating to Equal Weight from Underweight, increasing the price target to $20.00 due to a more favorable outlook on the exchange market trajectory in 2026. Raymond James reiterated its Outperform rating with a $30.00 price target following a federal judge’s decision on marketplace regulations affecting the company.
Furthermore, Oscar Health announced changes to Mr. Schlosser’s role, transitioning him from President of Technology and Chief Technology Officer to Co-Founder & Advisor to the CEO. He will continue to support AI and digital health initiatives. The company also reported a spike in options trading activity, with a total of 52,384 contracts, predominantly call options. These recent developments reflect significant strategic and market positioning efforts by Oscar Health.